“We have 19,883 new and confirmed cases of #coronavirus infection from the following voivodships: Mazowieckie (3340), Śląskie (2214), Dolnośląskie (2091), Małopolskie (1608), Pomeranian (1313), Greater Poland (1174), Łódź (1154), and West Pomeranian Voivodeship (1146), Świętokrzyskie (870), Opole (861), Kuyavian-Pomeranian (854), Warmian-Masurian (788), Podkarpackie (777), Lublin (627), Lubuskie (586), Podlasie (480) “- it was reported The Ministry of Health in the latest announcement.
“112 people have died due to COVID-19, while 491 people have died due to the coexistence of COVID-19 with other diseases” – added the release.
In total, 772,000 have been recorded since the beginning of the pandemic. 823 cases of coronavirus infection. 11 thousand died 451 people.
Due to COVID-19, there are 22,000 in hospitals. 812 patients, of which 2 thous. 117 of them are connected to respirators, the Ministry of Health announced on Wednesday.
On Tuesday 221 more patients were hospitalized than on Monday, and 3 fewer patients required respiratory support.
According to the data of the Ministry of Health, a total of 36,000 were prepared for patients with COVID-19. 802 beds and 2 thousand. 829 respirators. Patients with COVID-19 still have 13,000 at their disposal. 990 seats and 712 respirators.
According to the Ministry of Health, 415,000 are in quarantine. 601 people, and sanitary and epidemiological supervision covered 25 thousand. 653 people. 342,000 recovered 883 sick.
On Monday, 22 thousand people were occupied, according to the Ministry of Health. 458 beds and 2 thousand. 103 respirators, on Sunday 21 thousand. 988 beds and 2 thousand. 114 respirators, on Saturday 22 thousand. 320 beds and 2 thousand. 126 respirators. 22,000 were hospitalized on Friday. 298 people, including 2 thousand. 47 patients required respiratory support.
The effectiveness of the vaccine was calculated on the basis of confirmed coronavirus infections among clinical trial participants. Among 30 thousand 95 study participants became infected, 90 of whom were treated with placebo instead of the vaccine.
According to the American company Moderna, 11 of the infections were severe cases, and all of them were in the control group. 15 people infected are seniors.
The study found no significant side effects of the vaccine, most of which were “mild or moderate”. The most common side effect after the first dose of the vaccine was pain at the injection site (2.7%), followed by fatigue (9.7%), muscle pain (8.9%), and joint pain after the second dose (5.2%). percent) and headache (4.5 percent). These symptoms “were generally short-lived,” the company said.
The final assessment of effectiveness may still change as studies continue and more cases are detected. The company plans to apply for an emergency approval in the US within weeks, but only vulnerable people will get it first. According to the company’s estimates, the wide distribution of the preparation will take place at the turn of the first and second quarter of 2021 at the earliest.
Moderna is the second Western company to publish the preliminary results of Phase 3 clinical trials. Previously, BioNTech and Pfizer did it, which estimated the effectiveness of the joint vaccine at over 90 percent. Both agents are next-generation mRNA vaccines and are the first of their kind.
The most optimistic is prof. John Bell of Oxford University. In his opinion, it will be possible to return to normal activity in the spring of 2021. Then the expected decrease in infections will occur and the first group of people will be vaccinated against the SARS-CoV-2 coronavirus. In Europe, e.g. in Great Britain, the first people are to receive such a preparation at the end of 2020.
– I am probably the first specialist to say so, but I am talking about it with conviction – said prof. Bell.
Prof. Ugur Sahin, one of the makers of the vaccine from the pharmaceutical concern Pfizer and BioNTech, is however more cautious. In a statement for the BBC, he says that in his opinion the prospect of returning to normal life in the fall and winter of 2021 is more realistic. He believes that vaccination against COVID-19 will be popularized by then.
– I am convinced that the transmission of (virus) between people will be reduced by an effective vaccine, perhaps not by 90%, but by 50%. The specialist said. In his opinion, this should result in a significant reduction in the size of the pandemic.
We are glad that you are with us. Subscribe to the Onet newsletter to receive the most valuable content from us
Source: Onet, Twitter, PAP
/cdn4.vogel.de/infinity/white.jpg?resize=150%2C150&ssl=1 "Insider Research || News || New eBook: Compliance and Cyber Insurance")